Source: Annual Congress 2005 - Biological and molecular features in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
G. E. Carpagnano, M. P. Foschino Barbaro, S. Tommasi, O. Resta, F. Carpagnano, G. Di Gioia, M. De Lena, A. Paradiso (Foggia, Bari, Italy). Potentiality of detectionof microsatellite alterations in exhaled breath condensate of smokers as a tool for tumor susceptibility. Eur Respir J 2005; 26: Suppl. 49, 2153

Member's Comments

No comment yet.

Related content which might interest you: Metabolomic/proteomic analysis of biomarkers in exhaled breath condensates Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow Year: 2008 Reproducibility of exhaled breath condensate markers Source: Eur Respir J 2008; 32: Year: 2008 Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate Source: Eur Respir J 2006; 28: 1036-1041 Year: 2006 Inflammatory markers in exhaled breath condensate of two COPD phenotypes Source: Eur Respir J 2005; 26: Suppl. 49, 260s Year: 2005 Better characterization of local inflammation in COPD: detection of new biomarkers in exhaled breath condensate Source: Eur Respir J 2006; 28: Suppl. 50, 747s Year: 2006 3p microsatellite evaluation in NSCLC exhaled breath condensate: validation study Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 The validation of assays used to measure biomarkers in exhaled breath condensate Source: Eur Respir J 2008; 32: 1408-1409 Year: 2008 Separate lung exhaled breath condensate collection confirms intrapulmonary origin of exhaled breath condensate acidification Source: Eur Respir J 2007; 30: Suppl. 51, 364s Year: 2007 Standardization of collection of exhaled breath condensate (EBC) for disease markers in use of different condensers Source: Eur Respir J 2003; 22: Suppl. 45, 448s Year: 2003 Periostin in exhaled breath condensate as a biomarker of different severe asthma phenotypes. Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Validation of eicosanoid measurements in exhaled breath condensate Source: Eur Respir J 2002; 20: Suppl. 38, 422s Year: 2002 Exhaled biomarkers in lung cancer Source: Eur Respir J 2009; 34: 261-275 Year: 2009 Exhaled breath condensate sample collection: standards and open issues Source: Eur Respir Monogr 2010; 49: 152-161 Year: 2010 Exhaled breath condensate is not suitable to detect EGFR somatic mutations Source: Eur Respir J 2008; 32: 1123-1124 Year: 2008 Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation Year: 2008 Relationship of inflamamatory markers in blood and exhaled breath condensate in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 283s Year: 2006 Is the analysis of torbamycin in exhaled breath condensate a diagnostic tool to monitor pulmonary drug deposition? Source: Eur Respir J 2004; 24: Suppl. 48, 386s Year: 2004 Proteins in exhaled breath condensate: identification and pattern Source: Annual Congress 2007 - Noninvasive evaluation of airway diseases Year: 2007 Comparison of two devices and two breathing patterns for exhaled breath condensate sampling Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 Structures of an exhaled breath condensate in lung diseases Source: Eur Respir J 2005; 26: Suppl. 49, 525s Year: 2005